Last reviewed · How we verify
Zoliflodacin Patheon
Zoliflodacin Patheon is a Small molecule drug developed by Global Antibiotics Research and Development Partnership. It is currently in Phase 1 development.
At a glance
| Generic name | Zoliflodacin Patheon |
|---|---|
| Sponsor | Global Antibiotics Research and Development Partnership |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zoliflodacin Patheon CI brief — competitive landscape report
- Zoliflodacin Patheon updates RSS · CI watch RSS
- Global Antibiotics Research and Development Partnership portfolio CI
Frequently asked questions about Zoliflodacin Patheon
What is Zoliflodacin Patheon?
Zoliflodacin Patheon is a Small molecule drug developed by Global Antibiotics Research and Development Partnership.
Who makes Zoliflodacin Patheon?
Zoliflodacin Patheon is developed by Global Antibiotics Research and Development Partnership (see full Global Antibiotics Research and Development Partnership pipeline at /company/global-antibiotics-research-and-development-partnership).
What development phase is Zoliflodacin Patheon in?
Zoliflodacin Patheon is in Phase 1.